Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, September 24, 2021 · 552,194,796 Articles · 3+ Million Readers

Adult Vaccines Market Report to 2031: Visiongain Research Inc.

/EIN News/ -- Visiongain has published a new report on Adult Vaccines Market Report to 2031: Forecasts By Vaccine (Influenza, Tetanus /Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), By Vaccine Type (Monovalent and Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines) PLUS COVID-19 Recovery Scenarios.

COVID-19 Impact on Adult Vaccines Market

COVID-19 pandemic has affected more than 200 countries worldwide. Companies have been pressured to upsurge production capacity and raise the supply of products and other commodities. The pandemic has negatively impacted all the countries and businesses across the world.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/adult-vaccines-market/#download_sampe_div

Visiongain has evaluated the present and possible impact of the pandemic on the global adult vaccine market as UNICEF, PAHO, World Health Organization, and other regular immunization programs have been stopped due to the outbreak of the deadliest virus. Hence, it is making people more susceptible to multiple infections and reduced the immunization campaigns worldwide triggered huge damage to healthcare systems. Therefore, the death rate will be high globally. This would have extremely worse inferences than the COVID-19 virus itself. Gavi, The Vaccine Alliance reported that the organization will not vaccinate nearly 13.5 million people in the least developing countries. The majority of manufacturers across the world are focusing on the development of the SARS-CoV-2 vaccine. Though, this shift is expected to harm the other segments of the market.

Market Drivers

A rise in Cases of Infectious Diseases in the Adults
The adult vaccines market is expected to attain a significant growth rate due to the increasing incidence of infectious viruses among the elderly population along with growing alertness regarding the benefits of immunization. As per the World Health Organization (WHO), there is a rise in the aging population. From 2000 to 2050, people aged 60 and over are anticipated to increase from 600 million to around 2 billion, with 80% of adults living in emerging nations, with a majority of females. The progress of rising susceptibility to numerous infections as getting old is higher and the number of vaccine shots essential to target these people is expected to outpace in the given time frame.

Rising Focus on Immunization Programs
The rising number of non-government and government campaigns to spread consciousness regarding the significance of immunization to prevent life-threatening infections, in turn, is anticipated to boost the global adult vaccines market growth. For instance, the World Health Organization collaborated with the Bill & Melinda Gates Foundation and National Institute of Allergy & Infectious Diseases to launch the Global Vaccine and Immunization Research Forum (GVIRF) to start research and development on the vaccines in 2012. Furthermore, on 3rd November 2020, Godrej Appliances collaborated with Indian Govt’s Universal Immunization Program. The company commissioned around 11,856 units of vaccine refrigerators and deep freezers to support the Universal Immunization Program.

Market Opportunities

High Growth Scenarios in Emerging Markets
Potential global players, majorly from developing countries are more focused to develop unique vaccines to fulfill the global demand as there is a growth in diseases with a high mortality rate. For instance, on 8th October 2020, Cipla Ltd and Hetero Labs approved to marketing and distribution of its generic versions of remdesivir in India. It is the first inoculation to show some improvement in COVID-19 trials. Moreover, on 29th September 2020, the Serum Institute of India (SII) announced that the company has collaborated with Gavi and the Bill & Melinda Gates Foundation to accelerate the manufacturing and distribution of up to 100 million dosages of COVID-19 vaccines low-and middle-income countries (LMICs).

Get Detailed TOC @ https://www.visiongain.com/report/adult-vaccines-market/#download_sampe_div

How the Adult Vaccines Market report helps you
In summary, our 500+ page report provides you with the following knowledge:

  • Revenue forecasts to 2031 for Adult Vaccines Market, with forecasts for Vaccine, Vaccine Type, and Technology, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Adult Vaccines market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Adult Vaccines Market.

Competitive Landscape

Key players operating in the global Adult Vaccines market are Merck & Co., Sanofi Pasteur, GlaxoSmithKline Plc, Pfizer, Inc., Johnson & Johnson, CSL Limited, Serum Institute of India, AstraZeneca Plc., Medimmune, and BioCSL (Seqirus).

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Adult Vaccines Market and leading companies. You will find data, trends, and predictions.

Find more Visiongain research reports on Therapeutic Drugs Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs. 

Contact:

Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.


Primary Logo

Powered by EIN News
Distribution channels: Business & Economy


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release